DUOBRII

Peak

halobetasol propionate and tazarotene

NDATOPICALLOTION
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2

Mechanism of Action

signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown. Tazarotene is a retinoid prodrug which is converted to its active form, tazarotenic acid, the carboxylic acid of tazarotene, by deesterification. Tazarotenic…

Pharmacologic Class:

Retinoid

Indications (1)

Clinical Trials (2)

NCT05608499Phase 3Terminated

Duobrii Treatment of Acne Keloidalis Nuchae (AKN)

Started Oct 2022
15 enrolled
Acne Keloidalis NuchaeAKN
NCT04720105Phase 4Completed

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis

Loss of Exclusivity

LOE Date
Jun 6, 2036
124 months away
Patent Expiry
Jun 6, 2036

Patent Records (5)

Patent #ExpiryTypeUse Code
8809307
Nov 2, 2031
Product
11839656
Nov 2, 2031
U-2625
11957753
Nov 2, 2031
Product
11986527
Nov 2, 2031
U-2625
12076403
Nov 2, 2031
Product